Sanjay Raikar, MD
Hospitalist · Michigan City, INNPI 1780990283
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 32 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 13.1% — the pattern of someone who eats at a lot of different presentations. Among hospitalist clinicians in IN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 32 payments — averaging $103.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$433
- Boston Scientific$413
- Lilly USA, LLC$250
- Novo Nordisk$235
- AstraZeneca$235
- Amgen$220
- plus $2K from 14 others
What the payments were for
- Food & beverage$3,313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 4 | $433 |
| Boston Scientific | 3 | $413 |
| Lilly USA, LLC | 2 | $250 |
| Novo Nordisk | 2 | $235 |
| AstraZeneca | 3 | $235 |
| Amgen | 2 | $220 |
| Johnson & Johnson(2 entities) | 2 | $209 |
| Cook Medical LLC | 1 | $137 |
| ANI Pharmaceuticals, Inc. | 1 | $125 |
| Vifor Pharma, Inc. | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $125 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Lexicon Pharmaceuticals, Inc. | 1 | $123 |
| Exact Sciences | 1 | $114 |
| Boehringer Ingelheim | 1 | $110 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $107 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $100 |
| EKOS Corporation | 1 | $75 |
| Medtronic | 1 | $39 |
| Baxter Healthcare | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$360
- WATCHMAN Access System$267
- WATCHMAN FLX$146
- Zilver Vena$137
- Monarch Platform$131
- Veltassa$125
- NEXLIZET$125
- NEXLETOL$125
- Ozempic$125
- SOLIQUA 100/33$125
- KRYSTEXXA$125
- PURIFIED CORTROPHIN GEL$125
- Inpefa$123
- BREZTRI$114
- The Cologuard Plus Collection Kit$114
- Tresiba$110
- COSENTYX$103
- TRULANCE$100
- LifeVest$100
How this compares
$3,313 in reported general payments places this provider in the 95th percentile of 423 hospitalist providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 882 | $156,918 |
| XareltoRivaroxaban | 141 | $26,919 |
| EntrestoSacubitril/Valsartan | 127 | $25,672 |
| MyrbetriqMirabegron | 130 | $18,864 |
| FetrojaCefiderocol Sulfate Tosylate | 12 | $17,129 |
| OzempicSemaglutide | 15 | $15,107 |
| FarxigaDapagliflozin Propanediol | 78 | $12,518 |
| RybelsusSemaglutide | 12 | $12,357 |
| TrulicityDulaglutide | 19 | $10,897 |
| RytaryCarbidopa/Levodopa | 32 | $10,764 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $9,195 |
| Atorvastatin Calcium | 1,617 | $9,113 |
| Daptomycin | 15 | $8,632 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $7,193 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $6,726 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $235 | $27,46427 claims |
| Johnson & JohnsonXarelto | $209 | $26,919141 claims |
| NovartisEntresto | $433 | $25,672127 claims |
| AstraZenecaFarxiga, Brilinta | $235 | $15,70889 claims |
| Lilly USA, LLCTrulicity | $250 | $10,89719 claims |
| AmgenCorlanor | $220 | $5,31421 claims |
| Sanofi-aventis U.S. LLCLantus | $125 | $3,44148 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 423 hospitalist providers in Indiana.
Other hospitalist in Michigan City
- Ossama ZorubMichigan City$2K
- Harpreet SinghMichigan City$1K
- Anil ChawlaMichigan City$1K
- Alex HtunMichigan City$933
- Nirmala MurugavelMichigan City$920
- Zain SheikhMichigan City$914
- Joseph AbdayemTerre Haute$13K
- James KruegerEvansville$11K
- Yu LiuDecatur$6K
- Laarni MorenoElkhart$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.